State of Alaska Department of Revenue Trims Stake in IQVIA Holdings Inc. $IQV

State of Alaska Department of Revenue decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 32.9% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 18,575 shares of the medical research company’s stock after selling 9,112 shares during the period. State of Alaska Department of Revenue’s holdings in IQVIA were worth $3,528,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of IQV. Artisan Partners Limited Partnership purchased a new position in IQVIA in the 2nd quarter worth approximately $515,772,000. Norges Bank bought a new position in shares of IQVIA during the 2nd quarter valued at about $270,160,000. AQR Capital Management LLC raised its holdings in shares of IQVIA by 130.2% during the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after buying an additional 879,701 shares in the last quarter. Laurel Wealth Advisors LLC raised its stake in shares of IQVIA by 15,755.2% during the second quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock worth $122,857,000 after acquiring an additional 774,681 shares in the last quarter. Finally, Nordea Investment Management AB boosted its stake in shares of IQVIA by 41.7% in the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after purchasing an additional 606,391 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Insider Activity

In related news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.60% of the stock is currently owned by insiders.

IQVIA Trading Down 0.6%

Shares of IQV opened at $240.94 on Tuesday. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. The firm’s 50-day moving average price is $224.91 and its 200-day moving average price is $201.35. The firm has a market capitalization of $41.03 billion, a price-to-earnings ratio of 33.05, a PEG ratio of 2.47 and a beta of 1.36.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter in the prior year, the business earned $2.84 EPS. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Truist Financial upped their price target on shares of IQVIA from $265.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday. Robert W. Baird set a $258.00 price target on IQVIA and gave the stock an “outperform” rating in a research note on Wednesday, October 29th. UBS Group increased their price objective on IQVIA from $250.00 to $280.00 and gave the company a “buy” rating in a research note on Thursday. Baird R W raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 29th. Finally, Barclays set a $230.00 price target on shares of IQVIA in a research report on Monday, December 15th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $249.19.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.